RESUMO
As major prescribers of oral anticoagulants, cardiologists must be familiar with strategies to manage bleeding, the principal complication associated with all anticoagulants, and to reverse anticoagulant effects in acute-care settings. The purpose of this manuscript is to review currently available information regarding dabigatran and rivaroxaban, the 2 novel oral anticoagulants approved to date in the United States. Further, we suggest reasonable interventions for the clinician faced with a patient who suffers a major bleeding event while receiving one of these agents. Data sources were peer-reviewed publications, US Food and Drug Administration documents in the public domain, and approved US prescribing information for dabigatran (Pradaxa) and rivaroxaban (Xarelto). Strategies for management of bleeding and reversal of anticoagulant effects from warfarin include vitamin K, fresh frozen plasma, and prothrombin complex concentrates. For rivaroxaban and dabigatran, appropriate therapies include support and observation, which are likely to be effective for the majority of patients because of the short half-lives of these agents. In severe life-threatening hemorrhage, clotting-factor substitutes may be appropriate in certain situations. Validated protocols specific to each agent remain to be developed.
Assuntos
Anticoagulantes/efeitos adversos , Serviços Médicos de Emergência , Hemorragia/induzido quimicamente , Hemorragia/terapia , Administração Oral , Anticoagulantes/administração & dosagem , HumanosRESUMO
Hyperglycemia and insulin resistance are common among critically ill patients and occur in patients with or without a history of diabetes mellitus. All patients undergoing critical illness are at risk for stress-induced hyperglycemia. Some patients may be at greater risk for hyperglycemia than others when considering underlying disease states and iatrogenic factors. Many recent studies demonstrate that tight glucose control can decrease morbidity and mortality associated with critical illness. This article reviews the pathophysiology behind stress-induced hyperglycemia, the evidence to support tight glycemic control, and the importance of an intensive insulin therapy protocol to standardize treatment among critical care patients.
Assuntos
Cuidados Críticos/métodos , Estado Terminal , Hiperglicemia/terapia , Glicemia/metabolismo , Protocolos Clínicos , Cuidados Críticos/normas , Estado Terminal/epidemiologia , Epinefrina/fisiologia , Medicina Baseada em Evidências , Glucagon/fisiologia , Humanos , Hidrocortisona/fisiologia , Hiperglicemia/diagnóstico , Hiperglicemia/etiologia , Hiperglicemia/metabolismo , Hipoglicemiantes/uso terapêutico , Sistema Hipotálamo-Hipofisário/fisiopatologia , Insulina/uso terapêutico , Resistência à Insulina/fisiologia , Morbidade , Norepinefrina/fisiologia , Sistema Hipófise-Suprarrenal/fisiopatologia , Guias de Prática Clínica como Assunto , Fatores de Risco , Sepse/etiologia , Sepse/prevenção & controle , Estresse Fisiológico/complicações , Estresse Fisiológico/metabolismo , Estresse Fisiológico/fisiopatologia , Taxa de Sobrevida , Resultado do Tratamento , Fator de Necrose Tumoral alfa/fisiologiaRESUMO
BACKGROUND: Prophylaxis for venous thromboembolism (VTE) in head injured patients has avoided heparin products because of concern for exacerbating intracranial bleeding. The purpose of this study was to evaluate the safety of unfractionated heparin (UFH) for VTE prophylaxis after traumatic brain injury. METHODS: We retrospectively evaluated the early use of UFH in patients sustaining a severe closed head injury (Abbreviated Injury Scale score > 3) from January 1, 2000, through December 31, 2000. Two groups were formed on the basis of the timing of UFH administration: within 72 hours of admission (Early group), or after the third day of hospitalization (Late group), if at all. Intracranial bleeding related to UFH administration was assessed by computed tomographic scan of the head and/or clinical examination. RESULTS: Sixty-four of 76 patients with intracranial blood on admission head computed tomographic scan fulfilled study criteria. Seventy-three percent (n = 47) were in the Early group and 27% (n = 17) were in the Late group. None of the Early group had an increase in intracranial bleeding or deterioration on neurologic examination as a result of UFH administration. However, there was no statistical difference in VTE events between the two groups. CONCLUSION: Early use of UFH in the severe head injured patient does not increase bleeding complications.